JP2023513188A5 - - Google Patents
Info
- Publication number
- JP2023513188A5 JP2023513188A5 JP2022547885A JP2022547885A JP2023513188A5 JP 2023513188 A5 JP2023513188 A5 JP 2023513188A5 JP 2022547885 A JP2022547885 A JP 2022547885A JP 2022547885 A JP2022547885 A JP 2022547885A JP 2023513188 A5 JP2023513188 A5 JP 2023513188A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- gene
- protein
- subject
- expression level
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062971767P | 2020-02-07 | 2020-02-07 | |
| US62/971,767 | 2020-02-07 | ||
| US202062989486P | 2020-03-13 | 2020-03-13 | |
| US62/989,486 | 2020-03-13 | ||
| US202063047155P | 2020-07-01 | 2020-07-01 | |
| US63/047,155 | 2020-07-01 | ||
| US202063064314P | 2020-08-11 | 2020-08-11 | |
| US63/064,314 | 2020-08-11 | ||
| PCT/IB2021/050974 WO2021156831A1 (en) | 2020-02-07 | 2021-02-05 | Mirna-485 inhibitor for gene upregulation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023513188A JP2023513188A (ja) | 2023-03-30 |
| JP2023513188A5 true JP2023513188A5 (cg-RX-API-DMAC7.html) | 2024-02-14 |
Family
ID=77200819
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022547885A Pending JP2023513188A (ja) | 2020-02-07 | 2021-02-05 | 遺伝子の発現増加のためのmirna-485阻害剤 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230126157A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4100067A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023513188A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220154104A (cg-RX-API-DMAC7.html) |
| CN (1) | CN115443154A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021216720A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3166709A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022009448A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021156831A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024228119A1 (en) * | 2023-05-01 | 2024-11-07 | Biorchestra Co., Ltd. | Mirna-485 inhibitors |
| WO2024228118A1 (en) * | 2023-05-01 | 2024-11-07 | Biorchestra Co., Ltd. | Mirna-485 inhibitors |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9951330B2 (en) * | 2013-07-11 | 2018-04-24 | The Trustees Of Columbia University In The City Of New York | Micrornas that silence tau expression |
| DK3378482T5 (da) * | 2015-11-19 | 2024-09-30 | Univ Nagoya City Public Univ Corp | Formulering til administration af antitumorlægemiddel |
| RU2016146594A (ru) * | 2016-11-28 | 2018-05-28 | Общество С Ограниченной Ответственностью "Биофарм-Меморейн" | Средство для лечения деменции различной этиологии |
| WO2018139819A1 (ko) * | 2017-01-26 | 2018-08-02 | 주식회사 바이오오케스트라 | 마이크로 rna를 이용한 뇌 질환 예방 또는 치료 용도 |
| CN107287319B (zh) * | 2017-07-13 | 2021-07-02 | 青岛大学 | miRNA-485-5p核苷酸类似物及其反义核苷酸的应用和应用其的产品 |
| WO2019240223A1 (ja) * | 2018-06-13 | 2019-12-19 | 公益財団法人川崎市産業振興財団 | 数平均分子量が3kDa~10kDaであるPEGブロックとカチオン性ポリマーとのブロックコポリマーと、アンチセンスオリゴヌクレオチドとを含む、ポリイオンコンプレックスミセル |
| KR20220024160A (ko) * | 2019-06-17 | 2022-03-03 | 주식회사 바이오오케스트라 | 마이크로rna를 이용하여 알츠하이머 질환 동물 모델을 준비하기 위한 조성물 및 방법 |
-
2021
- 2021-02-05 CN CN202180026126.4A patent/CN115443154A/zh active Pending
- 2021-02-05 EP EP21751057.7A patent/EP4100067A4/en not_active Withdrawn
- 2021-02-05 JP JP2022547885A patent/JP2023513188A/ja active Pending
- 2021-02-05 CA CA3166709A patent/CA3166709A1/en active Pending
- 2021-02-05 US US17/760,343 patent/US20230126157A1/en not_active Abandoned
- 2021-02-05 MX MX2022009448A patent/MX2022009448A/es unknown
- 2021-02-05 KR KR1020227030525A patent/KR20220154104A/ko active Pending
- 2021-02-05 WO PCT/IB2021/050974 patent/WO2021156831A1/en not_active Ceased
- 2021-02-05 AU AU2021216720A patent/AU2021216720A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022538868A5 (cg-RX-API-DMAC7.html) | ||
| Yang et al. | Efficient cytosolic delivery of siRNA using HDL‐mimicking nanoparticles | |
| EP3411059B1 (en) | Method to enhance the efficiency of systemic aav gene delivery to the central nervous system | |
| Liu et al. | Investigation of the performance of PEG–PEI/ROCK-II-siRNA complexes for Alzheimer's disease in vitro | |
| US10113151B2 (en) | Composition of viral vectors in lecithin liposomes, preparation method and treatment methods | |
| Rodriguez-Gascon et al. | Vaginal gene therapy | |
| Reimondez-Troitiño et al. | Versatile protamine nanocapsules to restore miR-145 levels and interfere tumor growth in colorectal cancer cells | |
| JP2023532536A5 (cg-RX-API-DMAC7.html) | ||
| Fraga et al. | PEGylated cationic nanoemulsions can efficiently bind and transfect pIDUA in a mucopolysaccharidosis type I murine model | |
| Sarisozen et al. | Lipid-based siRNA delivery systems: challenges, promises and solutions along the long journey | |
| JP2023513190A5 (cg-RX-API-DMAC7.html) | ||
| Botto et al. | Cationic solid lipid nanoparticles as non viral vectors for the inhibition of hepatocellular carcinoma growth by RNA interference | |
| Sasaki et al. | Alpha-dystroglycan binding peptide A2G80-modified stealth liposomes as a muscle-targeting carrier for Duchenne muscular dystrophy | |
| Ouyang et al. | A biomimic reconstituted high-density-lipoprotein-based drug and p53 gene co-delivery system for effective antiangiogenesis therapy of bladder cancer | |
| Oryan et al. | Basic concepts, current evidence, and future potential for gene therapy in managing cutaneous wounds | |
| JP2024501437A5 (cg-RX-API-DMAC7.html) | ||
| JP2023513189A5 (cg-RX-API-DMAC7.html) | ||
| Malfanti et al. | Control of cell penetration enhancer shielding and endosomal escape-kinetics crucial for efficient and biocompatible siRNA delivery | |
| IL316806A (en) | Compositions and methods for treating monogenic neurodevelopmental disorder | |
| Baradaran et al. | A novel method for the development of plasmid DNA-loaded nanoliposomes for cancer gene therapy | |
| US20260048147A1 (en) | Aav capsid proteins having mutations in the vp1 region | |
| Tahara et al. | A novel double-coating carrier produced by solid-in-oil and solid-in-water nanodispersion technology for delivery of genes and proteins into cells | |
| US12582669B2 (en) | Composition controlling pharmacokinetics in the body | |
| JP2024503302A5 (cg-RX-API-DMAC7.html) | ||
| JP2024503303A5 (cg-RX-API-DMAC7.html) |